Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2/3, Randomized, Double Blind, Placebo-controlled, Multicenter Study of NKTR-255 vs Placebo Following CD19-directed CAR-T Cell Therapy in Patients With Relapsed/Refractory Large B-cell Lymphoma

NCT05664217 is registered in ClinicalTrials.gov with Nektar Therapeutics as lead sponsor.

NCT NCT05664217
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05664217 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2/3, Randomized, Double Blind, Placebo-controlled, Multicenter Study of NKTR-255 vs Placebo Following CD19-directed CAR-T Cell Therapy in Patients With Relapsed/Refractory Large B-cell Lymphoma
Lead sponsor
Nektar Therapeutics
Phase
Phase 2/3
Overall status
Terminated
Start date
December 23, 2022
Completion date
August 16, 2024
Enrollment
15 (actual)
Sites
22

Conditions

As the registry lists them; a condition with its own page is linked.

non-hodgkin lymphoma, relapsed/refractory diffuse large b-cell lymphoma